MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research
MEI Pharma, Inc. (MEIP)
Last mei pharma, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.meipharma.com
Company Research
Source: GlobeNewswire
NEW YORK, NY, June 11, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MEI Pharma (Nasdaq: MEIP), a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and oncology drug development experience. The company’s stock has found strength in the recent past. Followed by promising partnerships, well-funded clinical programs, and most recently, promising data at ASCO for ME-401 and the potential for having a best-in-class P13K Delta oral inhibitor. The company’s share price has more than doubled since mid-May after the company announced its clinical data presentations were forthcoming. Analyst review, target price and pipeline analysis available here READ MORE Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/mei/ On June 4th, th
Show less
Read more
Impact Snapshot
Event Time:
MEIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEIP alerts
High impacting MEI Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
MEIP
News
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.MarketBeat
- MEI Pharma shelves plans for a second return of capital [Seeking Alpha]Seeking Alpha
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]Yahoo! Finance
MEIP
Earnings
- 2/13/24 - Miss
MEIP
Sec Filings
- 2/29/24 - Form EFFECT
- 2/28/24 - Form 424B5
- 2/21/24 - Form 8-K
- MEIP's page on the SEC website